More than 200 drug trials for Alzheimer's have failed or been abandoned since 2010, but two anti-amyloid infusion medications have netted FDA approval in recent years.

Scientists are reevaluating the causes of Alzheimer's beyond the amyloid hypothesis after numerous experimental drugs designed to target that theory have failed.

Early-onset Alzheimer's can appear as early as age 30, but estimates of its prevalence remain uncertain.

There are two FDA-approved blood tests that may detect early Alzheimer's disease.

Recent evidence raises the question of whether conventional wisdom about amyloid plaques and their connection to Alzheimer's is wrong.

"Plaques" and "tangles" are top potential causes of Alzheimer's—but questions remain

The exact causes of Alzheimer's—and how to treat it—continue to be the subject of intense research. Two leading factors are amyloid beta plaques and tau protein tangles, which effectively pile up in the brain and interfere with neurons and cause cell death, which manifests as memory loss and other symptoms.

How Alzheimer's disease becomes fatal

Despite more than 100,000 people with Alzheimer's dying each year, the specific cause of death is not the disease itself. Often, secondary diseases arise from complications with the disease, including pneumonia, severe falls, malnutrition, or infection. Read more about the range of complications caused by Alzheimer's here.

Does our fear of Alzheimer's create stigma around its treatment?

Surveys suggest our fear of Alzheimer's as a disease outranks that of heart disease and cancer. This piece argues our fear of aging and the slipping away of our mental capacities make it more difficult to treat Alzheimer's compassionately.

Explore this 1440 Original video offering a primer on Alzheimer's disease and what's known about its incidence, causes, and more.

A physician with a rare and deadly disease saved his own life by identifying an existing medication that he repurposed for his condition, and now he's using AI to try to do the same for other patients.

A top Alzheimer's researcher was accused of faking results

In 2021, an investigation revealed photo manipulation in images from a seminal 2006 paper by researcher Sylvain Lesné on the role of amyloid plaques in progressive Alzheimer's disease. The revelation rocked the field, leaving many wondering whether they had tried to build on fabricated results. (Some users may experience a paywall.)

A new daily MS pill is seeking regulatory approval in 2026

In clinical trials, Roche's fenebrutinib showed promise treating primary progressive MS and doubling relapse-free time in patients with relapsing MS as compared to existing treatment. But some liver damage and two possible drug-related deaths in the trials may make it difficult for the drug to net approval. (Some users may encounter a paywall.)

Companies developing new weight loss drugs

In recent years, weight loss drugs made a tremendous amount of money for Novo Nordisk and Eli Lilly. Other companies are developing new drugs to break into the market. This piece is a concise overview of companies creating and testing new drugs, how far along they are, and what Novo Nordisk and Eli Lilly are doing to compete with these emerging rivals.

Five to ten percent of Alzheimer's cases are early-onset

Early-onset Alzheimer’s typically emerges around 40 to 50 years of age, with devastating effects. This video follows Brian, diagnosed with the disease at age 54, as he travels the country as an advocate for research and discusses the progressive mental fog of Alzheimer’s.

US FDA recently approved the first new schizophrenia drug in decades

Though other antipsychotics block dopamine receptors, a new drug, Cobenfy, influences dopamine levels via a different pathway—it stimulates a pair of specialized receptors in the brain that control the release of a substance called acetylcholine. This alternative approach may help patients avoid serious side effects like weight gain. (Some users may experience a paywall.)

Late-stage clinical trials indicate that a common arthritis drug may be a promising treatment for a leading cause of hair loss.

Medical experts warn that completing genetic testing for Alzheimer's can be fraught, in part because there's a shortage of genetic counselors to help navigate the findings and their potential implications.

See how antidepressants—used by roughly 1 in 10 Americans—were discovered.

GLP-1 drugs are under investigation for treating Alzheimer's, Parkinson's, and drug addiction

Researchers are investigating GLP-1 applications for a variety of chronic conditions. One area of interest stems from how study participants using GLP-1 for diabetes and obesity reported describing less longing for wine and cigarettes while taking the medication—intriguing researchers about using the drugs for addiction applications. The drug, they theorize, could bind to receptors that mediate desire. (Some users may experience a paywall.)

Alzheimer's brain changes may begin years before symptoms appear.

Advanced drugs are closing in on cancer's deadliest mutations

The protein KRAS, mutated in many cancers, was deemed ‘undruggable’. Now scientists are hoping to save lives with a batch of new compounds that target it.

MS Drugs reduce inflammation, helping reduce relapses and slow disease progression

Disease-Modifying Drugs calm the body's inflammatory response to help stave off relapses—when new or existing MS symptoms show up for a day or longer. Avoiding smoking, exercising, reducing stress via mindfulness, checking for vitamin D deficiencies, drinking more water and eating well, all can slow disease progression. [The jury's still out on if HRT around the time of menopause may reduce dementia risk](https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00122-9/fulltext) Estrogen can reduce inflammation and support neural growth in the brain, and some research has suggested that beginning hormone replacement therapy around menopause—versus later in life—reduces Alzheimer's disease risk. Still, a recent systematic review concluded that taking HRT didn't affect dementia risk, regardless of when women started taking it, so the science remains unsettled.

Genetic blood test offers an estimated clock on when Alzheimer's symptoms may appear

The 2026 research finding from researchers at Washington University School of Medicine in St. Louis—if validated in broader populations—suggests that an already available blood test could estimate when Alzheimer's symptoms may begin within a margin of several years. The test detects a protein called p-tau217 found in blood plasma and the researchers incorporated the findings from that blood test into a statistical model to come up with the symptom timeline predictions.

Remylination is a huge focus for treatment—especially among older adults

Our ability to build new myelin sheaths for nerves degrades with age. There have been research advances boosting cells that support these processes and clear away debris from degraded myelin, but not yet any medications to boost myelination itself, which would aid nerve signaling and preserve nerve function.

DBS effectiveness in treating addiction remains uncertain amid inconsistent results

Critics argue that deep brain stimulation should be considered a last resort and not a scalable solution, given its high costs and trials limited to small samples. However, it has helped some patients manage severe opioid use disorder when conventional methods didn’t work.

Alzheimer's disease is the leading cause of dementia and risks rise after age 65

Read this primer about Alzheimer's disease and learn what factors increase the risk of this form of dementia, including genetics, being a woman, and health conditions, including high blood pressure.

Peptides like GLP-1 account for 31 of 370 new drugs approved by the US FDA between 2016 and 2023.

Researchers are exploring neural links between Alzheimer's and autism

Recent DNA sequencing and molecular biology studies suggest that similarities in genes, neural circuitry and patterns of disease warrant further exploration to potentially better understand both conditions and how to treat them. (Some users may encounter a paywall.)

There are more than 1,400 listed clinical trials for macular degeneration

The US database of clinical trials listed more than 1,400 macular degeneration trials in early 2026. That doesn't mean every trial is recruiting, but it does indicate there is significant interest in this medical condition.

As of February 2025, there are more than 150 clinical trials using CRISPR technology

The clinical trials are designed to determine whether experimental CRISPR-related therapies are safe and effective. The majority of trials involve treatments for blood disorders, including beta thalassemia.

It can take 10 to 15 years and more than $1B to develop a new antibiotic.

Why don't we just develop new antibiotics? In part, it's a complex scientific challenge, but market incentives also play a significant role. It can be time consuming, expensive, and most notably, we should use as little as possible to avoid driving further antibiotic resistance.

It's been about 30 years since a new hair loss drug was approved in the US, and women currently have no approved pills for hair loss.

The first identification of Alzheimer's was made in 1906.

See the evolution of Ebola vaccine and treatment development.

A planned clinical trial to treat a rare lysosomal storage disorder in utero has buoyed hopes of providing prenatal gene therapies, but it was still awaiting FDA approval to begin enrolling patients as of May 2026.

See this list of FDA-approved gene therapies, including offerings for inherited conditions as well as some forms of cancer.

A snapshot of progress in cancer treatments

The American Association for Cancer Research's "Snapshot of a Year of Progress" offers an overview of significant advancements in cancer research and treatment over the past year. Take a quick look at the rapid pace of scientific discovery and the translation of research findings into clinical practice. In 2024 alone, health regulators approved 15 new anticancer therapies alone.

In 2015, the FDA approved the first 3D-printed prescription tablet

Spritam, an epilepsy medication, had been too large and difficult to swallow, particularly due to its inability to dissolve easily. The new pill was designed with porous layers to enhance its dissolvability, paving the way for future 3D printing of drugs.

Read the original 1907 paper on the first known Alzheimer's patient, which was identified by Dr. Alois Alzheimer.

Poor sleep increases the risk of developing Alzheimer's, and a main reason appears to be that the brain disposes of toxic protein buildup during high-quality sleep.

Antidepressants alone may fail to help an estimated one-third to one-half of depressed patients.

The FDA rejected MDMA-assisted therapy for PTSD in 2024, calling for more research

The decision was considered to be a major setback for moving psychedelics into the mainstream for mental health treatment. Pharmaceutical company Lykos, who had applied for the approval, had already attracted significant support from patients, politicians on both sides of the aisle, and leaders in the mental health field.

Alzheimer's can cause significant brain shrinkage in the affected brain regions, including the hippocampus.

Minorities are largely underrepresented in medical research, which compromises our understanding of how conditions and treatments may affect various populations, but recent efforts, like the African Ancestry Neuroscience Research Initiative and new genome research studies, are seeking to close that gap.

Psychedelics are being fast-tracked for research after a 2026 executive order

Many such compounds (including LSD, psilocybin, and more) are classified as Schedule I drugs—illegal to possess and federally regarded as having no medical use. Researchers say such restrictions have created significant hurdles for formal clinical trials. With this executive order, the FDA will enable work particularly focused on depression, PTSD, and alcohol use disorder.

The 'Armamentarium' is a set of new gene therapy tools—including viruses that could shuttle therapies into the body—designed to fight brain diseases.

Alzheimer's in the United States is most prevalent in the South and the East.

86 commonly used drugs, including certain antidepressants, painkillers, and immunosuppressants, have different results for men and women, according to recent research.

Chronic drug use can cause neurological changes in the brain

Neuroscientist Judy Grisel breaks down the biology of addiction, examining how drugs hijack the brain’s natural reward system and create lasting neural changes. The physiological and neurological impacts of chronic drug use require a multifaceted treatment approach.

Some dementia cases may be linked to treatable microorganism infections in the brain.

Timeline of cancer research milestones

While cancer remains incurable, there's been so much progress in its treatment over the last two decades. Nature provides an abridged history of milestones and major triumphs in cancer research and treatment. Start in the year 2000, and see how much has changed in the first quarter of the new millennium